ARIMIDEX

국가: 인도네시아

언어: 인도네시아어

출처: Badan Pengawas Obat dan Makanan RI - Indonesian Food and Drug Supervisory Agency

제품 특성 요약 제품 특성 요약 (SPC)
08-12-2021

유효 성분:

ANASTROZOLE

제공처:

ASTRAZENECA INDONESIA - Indonesia

INN (International Name):

ANASTROZOLE

복용량:

1 MG

약제 형태:

TABLET SALUT SELAPUT

패키지 단위:

DUS, 2 BLISTER @ 14 TABLET SALUT SELAPUT

Manufactured by:

ASTRAZENECA PHARMACEUTICAL COMPANY LTD.

승인 날짜:

2017-11-09

제품 특성 요약

                                _Page 1 of 9 _
ARIMIDEX
®
_anastrozole _
FILM-COATED TABLETS
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film-coated tablet contains 1 mg anastrozole.
PHARMACEUTICAL FORM
Film-coated tablet.
White, round, biconvex tablet with logo on one side and strength on
the other.
THERAPEUTIC INDICATIONS
Treatment of advanced breast cancer in post-menopausal women with
oestrogen receptor
positive and or progesterone receptor positive.
Adjuvant treatment of post-menopausal women with hormone receptor
positive early
invasive breast cancer.
Adjuvant treatment of early breast cancer in hormone receptor positive
post-menopausal
women, who have received 2 to 3 years of adjuvant tamoxifen.
POSOLOGY AND METHOD OF ADMINISTRATION
Adults including elderly
: One 1 mg tablet to be taken orally once a day. For patients with
advanced breast cancer, ARIMIDEX should be continued until
tumour progression.
Children
: The use of ARIMIDEX is not recommended in children, as
efficacy has not been established.
Renal impairment
: No dose change is recommended in patients with mild or
moderate renal impairment.
Hepatic impairment
: No dose change is recommended in patients with mild hepatic
disease.
CONTRAINDICATIONS
ARIMIDEX is contraindicated in:
-
pre-menopausal women
-
pregnant or lactating women
-
patients with severe renal impairment (creatinine clearance less than
20 ml/min)
-
patients with moderate or severe hepatic disease
-
patients with known hypersensitivity to anastrozole or to any of the
excipients as
referenced on the _List of Excipients_
Oestrogen
–
containing therapies should not be co-administered with ARIMIDEX as
they
would negate its pharmacological action.
Concurrent tamoxifen therapy (see section _Interaction with other
medicinal products and _
_other forms of interaction_).
DISETUJUI OLEH BPOM : 02/11/2021
ID : EREG100422VR12100210
_Page 2 of 9 _
SPECIAL WARNINGS AND SPECIAL PRECAUTIONS FOR USE
ARIMIDEX is not recommended for use in children, as safety and
efficacy have not been
established in this group of patients.
ARIMI
                                
                                전체 문서 읽기
                                
                            

이 제품과 관련된 검색 알림

문서 기록보기